Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Income from Continuing Operations (2021 - 2025)

Valion Bio has reported Income from Continuing Operations over the past 5 years, most recently at 2479000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 73.24% year-over-year to 2479000.0; the TTM value through Sep 2025 reached 7392000.0, down 14.04%, while the annual FY2024 figure was 5700000.0, 169.14% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 2479000.0 at Valion Bio, down from 1934000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1229000.0 in Q3 2021 and troughed at 3018000.0 in Q2 2022.
  • A 5-year average of 1901526.32 and a median of 1934000.0 in 2025 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: crashed 136.15% in 2022 and later surged 37.6% in 2024.
  • Year by year, Income from Continuing Operations stood at 2292000.0 in 2021, then rose by 1.57% to 2256000.0 in 2022, then rose by 0.53% to 2244000.0 in 2023, then skyrocketed by 34.36% to 1473000.0 in 2024, then tumbled by 68.3% to 2479000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TIVC at 2479000.0 in Q3 2025, 1934000.0 in Q2 2025, and 1506000.0 in Q1 2025.